2007
DOI: 10.1111/j.1572-0241.2006.01062.x
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants

Abstract: Antisecretory agent or nitrate treatment is associated with reduced UGIB RR in patients taking NSAID or aspirin. Only PPI therapy was associated with a marked, consistent risk reduction among patients receiving all types of agents (including nonaspirin antiplatelet agents). Protection was not apparent in patients taking anticoagulants.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
200
2
9

Year Published

2008
2008
2015
2015

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 264 publications
(219 citation statements)
references
References 25 publications
8
200
2
9
Order By: Relevance
“…[1][2][3][4] However, the ROR for embolic/thrombotic events for clopidogrel was >2 (Table 5; ROR, 2.94 (95% CI, 2.84-3.05)). Patients at high risk for the occurrence or recurrence of embolic events are treated with clopidogrel.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…[1][2][3][4] However, the ROR for embolic/thrombotic events for clopidogrel was >2 (Table 5; ROR, 2.94 (95% CI, 2.84-3.05)). Patients at high risk for the occurrence or recurrence of embolic events are treated with clopidogrel.…”
Section: Discussionmentioning
confidence: 99%
“…1) The effects of PPIs on GI hemorrhagic events have been evaluated in a case-control study, 2) cohort studies, 3,4) and a randomized trial, 5) but are not well understood in clinical practice.…”
Section: Analysis Of the Interaction Betweenmentioning
confidence: 99%
“…При приеме 100 мг/сут АСК ОР кровотечений составил 2,7 (при 95% ДИ от 2,0 до 3,6), при дозе 200 мг/сут -3,8 (при 95% ДИ от 2,7 до 5,2), 300 мг/сут -6,1 (при 95% ДИ от 4,3 до 8,7), 500 мг/сут -7,5 (при 95% ДИ от 5,7 до 9,9), 1000 мг/сут 10,4 (при 95% ДИ от 6,1 до 17,8) [24].…”
Section: терапевтический архив 12 2014unclassified
“…В ходе крупного исследова-ния случай-контроль, изучавшего риск кровотечений из ПО ЖКТ, ассоциированных с приемом НПВП, дезагрегантов и анти-коагулянтов, общая клиническая эффективность ИПП в их сни-жении была в 2 раза выше, чем Н 2 -блокаторов (ОШ 0,33 при 95% ДИ от 0,27 до 0,39 против ОШ 0,65 при 95% ДИ от 0,50 до 0,85). ИПП превосходили Н 2 -блокаторы на фоне приема традицион-ных НПВП (ОШ 0,13 при 95% ДИ от 0,09 до 0,19 против ОШ 0,30 при 95% ДИ от 0,17 до 0,53) и низких доз АСК (ОШ 0,32 при 95% ДИ от 0,22 до 0,51 против ОШ 0,40 при 95% ДИ от 0,19 до 0,73) [24]. У пациентов с острым коронарным синдромом или инфар-ктом миокарда (ИМ) с подъемом сегмента ST ИПП в дозе 20 мг/сут превосходил фамотидин в дозе 40 мг/сут в профилактике ЖКО, связанных приемом с АСК, клопидогрела, эноксапарина или тромболитиков [41].…”
Section: терапевтический архив 12 2014unclassified
“…5 A recent case-control study of 372 LDA users and 381 controls reported that both PPIs (OR 0.32, 95% CI 0.22-0.51) and H2-receptor antagonists (H2-RAs, RR 0.40, 95% CI 0.19-0.73) significantly reduced upper GI bleeding. 17 The fact that H2-RAs appeared effective is unlike the superiority of PPI to H2-RAs seen among non-aspirin NSAID users and will need to be confirmed.…”
Section: Risk Factors For Upper Gi Bleedingmentioning
confidence: 99%